CVRx Funding Boost Will Sustain Barostim Heart Failure Device To US Launch

US heart failure device manufacturer CVRx has scored a double hit by securing $113 million in funding in this flat investor climate and by being one of the first into the US FDA’s EAP, designed to help innovative technologies get faster access to market. CVRx’s much larger rivals are doubtless watching events with an uneasy mix of interest and concern.

Privately-held CVRx Inc., developer of the Barostim Neo minimally invasive implantable system with separate indications for heart failure and resistant hypertension, has scored a major coup in securing $113 million in new funding in what remains a difficult market for medical device investment. The financing was led by Johnson & Johnson Development Corp., the venture arm of Johnson & Johnson.

Of equal significance, CVRx has also this year become one of the first beneficiaries of the US FDA’s Expedited Access...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By 

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.

Mapping The Power And Potential Of Europe’s Market Access Collaborations

 
• By 

Understand who’s influencing access decisions and how pharma can engage strategically across the continent.

Q&A: Commercializing Oncology Products, Strategic Insights For Drug Developers

 
• By 

John Arena, president of Global Pharma Services at Cencora, talks to In Vivo about how companies can strategize market entry for oncology products.

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

More from In Vivo

‘A Small Medtech Industry Ecosystem With An Outsized Global Influence’

 
• By 

Entrepreneurialism is in the blood of Israel’s medtech innovators, but in a changing medtech world, the local ecosystem must address funding gaps and manufacturing and infrastructure needs. So says Ruti Alon, experienced Israeli medtech leader, investor and co-chair of the Biomed Israel conference.

Dealmaking Quarterly Statistics, Q2 2025

 
• By 

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By 

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.